Class of 2024
For critical and innovative research dedicated to optimizing clinical trial design and execution resulting in accelerated discovery and development of tumor immunotherapies, and for extraordinary leadership in driving the advancement of novel and personalized therapeutics for patients with head and neck cancers as well as gastrointestinal malignancies.
*Full-length biography pending